First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin G (IgG) levels, one of the root causes of gMG, in both the adult and pediatric pivotal studies gMG patients taking IMAAVY demonstrated 20 months of lasting disease control and symptom relief in the pivotal Vivacity-MG3 study and ongoing open-label extension (OLE) SPRING HOUSE, Pa., April 30, 2025 /PRNewswire/ ...

Core Insights - Major companies are increasing dividends to provide stability and reliable returns to investors amid market volatility [1] Johnson & Johnson - Announced a 4.8% increase in its quarterly dividend, resulting in an annual dividend of $5.20 and a dividend yield of 3.35% [2][4] - Has a strong track record with 64 years of consecutive dividend increases and a 3-year annualized dividend growth rate of 5.43% [2][4] - Faces challenges from tariffs estimated to cost $400 million this year, primarily affecting its medical technology business [4] - Engaged in share buybacks, spending nearly $3.1 billion over the last 12 months, representing about 0.8% of its market capitalization [5] Costco Wholesale - Increased its quarterly dividend from $1.16 to $1.30 per share, marking a notable 12% increase [7] - The indicated annual dividend is $5.20, but the dividend yield is low at 0.53%, significantly below the average yield of 3.3% for the largest consumer staples stocks [8] - Focuses on share buybacks as its primary method of returning capital, having spent nearly $3.8 billion on buybacks in the last 12 months, resulting in a buyback yield of nearly 6.5% [8][9] NASDAQ - Announced a 13% increase in its quarterly dividend, bringing the new dividend to $0.27, with an indicated yield of approximately 1.42% [10][11][12] - The company has spent $260 million on share buybacks since the beginning of 2024, which is about 0.6% of its market capitalization, with additional buyback capacity of $1.6 billion [13] - Achieved a debt paydown yield of nearly 2% over the last 12 months, indicating effective debt management [13]

Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins. Many huge corporations have announced plans to invest billions in U.S. manufacturing. Trump scored a major victory when Taiwan Semiconductor Manufacturing NYSE: TSM promised to invest $100 billion in U.S. facilities. Chip behemoth NVIDIA NASDAQ: NVDA recently made a similar announcement. It plans to produce “half a trillion dollars of AI infrastructure in the United States” over the ne ...

Core Insights - Johnson & Johnson announced promising results from the Phase 2b SunRISe-1 study of TAR-200, showing over 82% of patients achieved complete response (CR) and more than half remained cancer-free for at least one year [1][4] - TAR-200 is positioned as a transformative treatment for patients with BCG-unresponsive, high-risk non-muscle invasive bladder cancer (HR-NMIBC), particularly those ineligible for radical cystectomy [1][8] Company Overview - Johnson & Johnson is focused on healthcare innovation, aiming to provide less invasive and more effective treatment options for complex diseases [9] - The company has initiated a new drug application with the FDA for TAR-200 under the Real-Time Oncology Review program, following its Breakthrough Therapy Designation [6][4] Study Details - The SunRISe-1 study enrolled 85 patients, with a complete response rate of 82.4% and a median duration of response of 25.8 months [1][7] - The study specifically targets patients with carcinoma in situ, with or without papillary disease, who have not responded to BCG therapy [7] Treatment Efficacy - The treatment demonstrated a high level of sustained disease control, with 52.9% of responders maintaining CR at one year and 86.6% remaining cystectomy-free [1][2] - Most treatment-related adverse events were mild, with only 3.5% of patients discontinuing treatment due to adverse effects [2] Market Context - Bladder cancer is among the ten most common cancers globally, with limited treatment options available for patients who do not respond to initial BCG therapy [1][8] - High-risk non-muscle invasive bladder cancer accounts for 15-44% of NMIBC cases, characterized by high-grade tumors and a tendency to recur [8]

Core Insights - The Phase 2b SunRISe-1 study results indicate that over 82% of patients with high-risk non-muscle invasive bladder cancer achieved a complete response (CR), with more than half remaining cancer-free for at least one year after treatment [1][2][3] - TAR-200, an intravesical gemcitabine releasing system, shows promise in transforming treatment outcomes for patients who are BCG-unresponsive and ineligible for radical cystectomy [1][2][3] Study Results - As of March 2025, 82.4% of the 85 enrolled patients achieved CR, with a 95% confidence interval of 72.6-89.8 [1] - 52.9% of responders maintained CR at one year, and the median duration of response was 25.8 months [1] - At 12 months, 86.6% of responders remained cystectomy-free [1] Treatment Tolerability - The treatment was well-tolerated, with 83.5% of patients experiencing mild treatment-related adverse events, primarily low-grade urinary symptoms [1] - Only 3.5% of patients discontinued treatment due to adverse events, and there were no treatment-related deaths [1] Clinical Significance - The results were presented at the 2025 American Urological Association Annual Meeting, highlighting the potential of TAR-200 to address significant unmet needs in bladder cancer treatment [1][2] - The study emphasizes the importance of patient quality of life, as TAR-200 is designed to fit into patients' lives without interrupting their daily activities [1][2] Background on Bladder Cancer - Bladder cancer is among the ten most common cancers globally, with limited treatment options available for patients who do not respond to initial BCG therapy [1][4] - High-risk non-muscle invasive bladder cancer (HR-NMIBC) accounts for 15-44% of NMIBC cases and is characterized by a high likelihood of recurrence and progression [4] About TAR-200 - TAR-200 is an investigational system designed for sustained local release of gemcitabine into the bladder, currently being evaluated in multiple clinical trials [2][3] - The ongoing Phase 2b SunRISe-1 study specifically targets patients with BCG-unresponsive HR-NMIBC [3]

President Donald Trump's macroeconomic policies are taking center stage on Wall Street. The 47th U.S. president has decided to implement aggressive tariffs on imported goods from most countries, although he recently paused these plans for 90 days. Regardless, corporations are looking for ways to avoid paying these tariffs.That includes two pharmaceutical leaders: Johnson & Johnson (JNJ -0.28%) and Novartis (NVS 0.95%). The industry has so far escaped Trump's tariffs, but that might not last for much longer, ...

The firsta approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis,1,2,3,4,5 guselkumab showed statistically higher rates of endoscopic normalisationb at Week 44 compared with placebo.2,6,7,8,9 Guselkumab is now approved for the treatment of ulcerative colitis in addition to existing indications of plaque psoriasis and psoriatic arthritis in the European Union.2 Beerse, Belgium (25 April 2025) – Johnson & Johnson today announced that the Europea ...

If you want to collect a lot of dividend income, it's important to focus on more than just a stock's current yield. Stocks that consistently grow their payouts over the years can be far more valuable investments to hang on to because that can ensure your dividend income is rising, possibly at a higher rate than inflation. Three stocks which have impressive track records for dividend growth are Walmart (WMT 0.20%), Johnson & Johnson (JNJ -1.49%), and Procter & Gamble (PG -1.27%). They are not just your regul ...

Market Overview - The Dow Jones Industrial Average, S&P 500, and Nasdaq Composite have all experienced double-digit percentage declines, with the Nasdaq entering a bear market with a loss exceeding 20% from its all-time high [2][3] - The recent declines have been characterized by their rapid velocity, with significant single-session point and percentage declines recorded [3] Tariff Policy Impact - President Trump's tariff policy has been a pivotal factor in the recent market downturn, with a 10% global tariff and higher reciprocal tariffs on countries with negative trade balances with the U.S. announced [4][5] - The potential for tariffs to increase domestic goods prices and reignite inflation is a concern, as input tariffs could make U.S. products less competitive [6] - Tariffs may also harm trade relations and create uncertainty in the market, as the president frequently changes which products or countries are affected [7] Investment Opportunities - The current market volatility presents an opportunity for long-term investors to acquire stocks at discounted prices [8] - Johnson & Johnson offers a 3.31% yield and has increased its annual payout for 63 consecutive years, indicating a strong dividend history [9] - Johnson & Johnson holds a AAA credit rating, reflecting confidence in its ability to service and repay debts [10][11] - The company's operating model is expected to remain stable despite tariff concerns, as demand for healthcare products is consistent [12] - Johnson & Johnson's focus on novel-drug development and its historically inexpensive stock valuation (14 times forward-year earnings) make it an attractive investment [14][15] Sirius XM Holdings - Sirius XM Holdings provides a 5.36% yield and operates as a legal monopoly in satellite radio, giving it pricing power over competitors [16][17] - The company generates 76% of its net sales from self-pay subscriptions, making it less vulnerable to economic downturns compared to traditional radio operators reliant on advertising [19] - Sirius XM's stock is valued at 6.6 times forward-year earnings, representing a 55% discount to its average forward P/E multiple from 2019 to 2024 [20]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 30, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...